PSA of ≥0.4 ng/mL Predicts PCa Progression

This article originally appeared here.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

(HealthDay News) -- A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in The Journal of Urology.

Amir Toussi, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues reviewed long-term prostatectomy outcomes to examine the most appropriate prostate-specific antigen cut point that predicts subsequent disease progression. Data were included for 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy.

The researchers found that a detectable prostate-specific antigen developed in 5,041 patients at a median postoperative follow-up of 9.1 years, and systemic progression developed in 512 patients. The percentage of patients experiencing a continued prostate-specific antigen increase over 5 years was 61, 67, and 74%, respectively, after reaching the prostate-specific antigen cut point of 0.2, 0.3, and 0.4 ng/mL, plateauing at 0.4 ng/mL. The strongest correlation between biochemical recurrence and systemic progression was seen for a single prostate-specific antigen cut point of 0.4 ng/mL or more.

"A prostate-specific antigen cut point of 0.4 ng/mL or greater reflects the threshold at which a prostate-specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression," the authors write.

Sources

  1. Toussi A, Stewart-Merrill SB, Boorjian SA, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol; doi: 10.1016/j.juro.2015.12.075.
  2. Tosoian JJ and Pierorazio PM. Optimizing Use of Serum Prostate Specific Antigen to Define Biochemical Recurrence—Is There a Method to the Madness? J Urol; doi: 10.1016/j.juro.2016.03.068.
Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters